Immunocore Holdings plc Increase Decrease Through Financing Cash Flows Liabilities Arising From Financing Activities
Immunocore Holdings plc (IMCR) reported Increase Decrease Through Financing Cash Flows Liabilities Arising From Financing Activities of GBP 32.83 million for the 12-month period ending 2020-12-31, per its 20-F filed 2021-03-25.
Discontinued › Cash Flow › Operating Activities
ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities · last filed 2021-03-25
| Period end | Increase Decrease Through Financing Cash Flows Liabilities Arising From Financing Activities 12 month |
|---|---|
| 2020-12-31 | 32.83M GBP 20-F · filed 2021-03-25 |
| 2019-12-31 | -4.04M GBP 20-F · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |